Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
Pediatr Int
; 65(1): e15588, 2023.
Article
en En
| MEDLINE
| ID: mdl-37658625
ABSTRACT
BACKGROUND:
The aim of this study was to evaluate the efficacy and safety of anti-interleukin-1 (IL-1) therapies in colchicine-resistant pediatric patients with familial Mediterranean fever (FMF).METHODS:
In this study, we retrospectively evaluated 656 children with FMF and 27 patients who had been treated with anti-IL-1 therapies (anakinra/canakinumab) . Clinical and laboratory features, MEFV gene mutations, treatment responses were investigated.RESULTS:
Twenty of the patients were treated with anakinra (the treatment of 6 patients who initially used anakinra was switched to canakinumab in the follow-up period), and 13 patients were treated with canakinumab. Clinical symptom and severity scores decreased in all patients A decrease in acute phase reactants was also observed in patients. A total of 18 (66%) patients had a M694V homozygous mutation, while 24 (89%) patients had a M694V mutation, at least in one allele.CONCLUSIONS:
FMF patients with colchicine resistance may progress to amyloidosis. IL-1 antagonist treatment could be used safely with a favorable outcome in pediatric patients with FMF resistance to colchicine therapy and/or who have renal amyloidosis.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Fiebre Mediterránea Familiar
/
Amiloidosis
Idioma:
En
Revista:
Pediatr Int
Asunto de la revista:
PEDIATRIA
Año:
2023
Tipo del documento:
Article